Interview with Dr. Ravindra Kolhe at AMP 2018 on tumor mutational burdon

TMB has emerged as a very promising marker for identifying patients who may respond to immunotherapies.
Dr. Kolhe talks about the key challenges in measuring TMB, and how the QIAseq panel helps to address them.